Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia
Background: Peripheral blood mononuclear cells (PBMNCs) showed encouraging short outcomes in the treatment of angiitis-induced no-option critical limb-threatening ischemia (AICLTI) in the pilot study. This study aimed to demonstrate the long-term outcomes of this treatment.Methods: From May 2014 to...
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-12-01
|
| Series: | Frontiers in Cardiovascular Medicine |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fcvm.2021.769472/full |
| _version_ | 1818983754835689472 |
|---|---|
| author | Xiaolang Jiang Hao Liu Tianyue Pan Shiyang Gu Yuan Fang Zheng Wei Gang Fang Bin Chen Junhao Jiang Yun Shi Peng Liu Weiguo Fu Zhihui Dong |
| author_facet | Xiaolang Jiang Hao Liu Tianyue Pan Shiyang Gu Yuan Fang Zheng Wei Gang Fang Bin Chen Junhao Jiang Yun Shi Peng Liu Weiguo Fu Zhihui Dong |
| author_sort | Xiaolang Jiang |
| collection | DOAJ |
| description | Background: Peripheral blood mononuclear cells (PBMNCs) showed encouraging short outcomes in the treatment of angiitis-induced no-option critical limb-threatening ischemia (AICLTI) in the pilot study. This study aimed to demonstrate the long-term outcomes of this treatment.Methods: From May 2014 to December 2018, patients diagnosed with AICLTI and treated by autotransplantation of PBMNCs in our center were enrolled and analyzed. The primary endpoint was major amputation-free survival (MAFS), the secondary endpoints included peak pain-free walking time (PPFWT), Wong-Baker FACES pain rating scale score (WFPRSS), labor recovery, ankle-brachial index (ABI), transcutaneous partial oxygen pressure (TcpO2), and SF-36v2 scores.Results: A total of 58 patients were enrolled. During a minimal follow-up of 36 months, the MAFS was 93.1% and the labor competence restored rate was 62.1%. The WFPRSS was decreased from 8.7 ± 1.6 to 1.6 ± 3.2, and PPFWT was significantly improved from 2.9 ± 4.2 min to 16.6 ± 6.9 min. The quality of life was also significantly improved at each follow-up point. Perfusion evaluating parameters, such as ABI and TcPO2, were also significantly improved. No critical adverse event was observed during the treatment and follow-up period.Conclusions: The treatment of AICLTI by autotransplantation of PBMNCs demonstrated encouraging long-term results. It could not only restore labor competence, improve the quality of life, but also significantly reduce the major amputation rate. |
| first_indexed | 2024-12-20T18:08:08Z |
| format | Article |
| id | doaj.art-c7a4908b4fc84691b68e5c92c03b68e4 |
| institution | Directory Open Access Journal |
| issn | 2297-055X |
| language | English |
| last_indexed | 2024-12-20T18:08:08Z |
| publishDate | 2021-12-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Cardiovascular Medicine |
| spelling | doaj.art-c7a4908b4fc84691b68e5c92c03b68e42022-12-21T19:30:33ZengFrontiers Media S.A.Frontiers in Cardiovascular Medicine2297-055X2021-12-01810.3389/fcvm.2021.769472769472Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening IschemiaXiaolang Jiang0Hao Liu1Tianyue Pan2Shiyang Gu3Yuan Fang4Zheng Wei5Gang Fang6Bin Chen7Junhao Jiang8Yun Shi9Peng Liu10Weiguo Fu11Zhihui Dong12Department of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Hematology, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Vascular Surgery, Institute of Vascular Surgery, Zhongshan Hospital, Fudan University, Shanghai, ChinaBackground: Peripheral blood mononuclear cells (PBMNCs) showed encouraging short outcomes in the treatment of angiitis-induced no-option critical limb-threatening ischemia (AICLTI) in the pilot study. This study aimed to demonstrate the long-term outcomes of this treatment.Methods: From May 2014 to December 2018, patients diagnosed with AICLTI and treated by autotransplantation of PBMNCs in our center were enrolled and analyzed. The primary endpoint was major amputation-free survival (MAFS), the secondary endpoints included peak pain-free walking time (PPFWT), Wong-Baker FACES pain rating scale score (WFPRSS), labor recovery, ankle-brachial index (ABI), transcutaneous partial oxygen pressure (TcpO2), and SF-36v2 scores.Results: A total of 58 patients were enrolled. During a minimal follow-up of 36 months, the MAFS was 93.1% and the labor competence restored rate was 62.1%. The WFPRSS was decreased from 8.7 ± 1.6 to 1.6 ± 3.2, and PPFWT was significantly improved from 2.9 ± 4.2 min to 16.6 ± 6.9 min. The quality of life was also significantly improved at each follow-up point. Perfusion evaluating parameters, such as ABI and TcPO2, were also significantly improved. No critical adverse event was observed during the treatment and follow-up period.Conclusions: The treatment of AICLTI by autotransplantation of PBMNCs demonstrated encouraging long-term results. It could not only restore labor competence, improve the quality of life, but also significantly reduce the major amputation rate.https://www.frontiersin.org/articles/10.3389/fcvm.2021.769472/fulladult stem cellsangiogenesisautologous stem cell transplantationCD34+cell transplantation |
| spellingShingle | Xiaolang Jiang Hao Liu Tianyue Pan Shiyang Gu Yuan Fang Zheng Wei Gang Fang Bin Chen Junhao Jiang Yun Shi Peng Liu Weiguo Fu Zhihui Dong Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia Frontiers in Cardiovascular Medicine adult stem cells angiogenesis autologous stem cell transplantation CD34+ cell transplantation |
| title | Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia |
| title_full | Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia |
| title_fullStr | Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia |
| title_full_unstemmed | Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia |
| title_short | Long-Term Outcomes of Peripheral Blood Mononuclear Cells in the Treatment of Angiitis-Induced No-Option Critical Limb-Threatening Ischemia |
| title_sort | long term outcomes of peripheral blood mononuclear cells in the treatment of angiitis induced no option critical limb threatening ischemia |
| topic | adult stem cells angiogenesis autologous stem cell transplantation CD34+ cell transplantation |
| url | https://www.frontiersin.org/articles/10.3389/fcvm.2021.769472/full |
| work_keys_str_mv | AT xiaolangjiang longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT haoliu longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT tianyuepan longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT shiyanggu longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT yuanfang longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT zhengwei longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT gangfang longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT binchen longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT junhaojiang longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT yunshi longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT pengliu longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT weiguofu longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia AT zhihuidong longtermoutcomesofperipheralbloodmononuclearcellsinthetreatmentofangiitisinducednooptioncriticallimbthreateningischemia |